Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 17 Parkinson's papers of 437 | 0.62 |
| pathways Reactome | 3 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 5708
Sealed predictions
- TOMM20 in dopamine neurons, braak+0.80 (p 0.010) → +0.21 (p 0.581)receipt 5715
In the sealed studies
- Mitochondrial quality control and Lewy stage: did not hold
Swarm cases
receipt 5715: TOMM20 in dopamine neurons, braak
- power
- full sample +0.51 (p 0.029, n 18), 95% CI +0.06 to +0.79. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.56 (p 0.015, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.57 (p 0.014, n 18). not the mix.
- skeptic
- leave-one-out range +0.45 to +0.66, sign flips 0; without severely affected donors +0.51 (p 0.029, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TOMM20 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts